PL1894564T3 - Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia - Google Patents

Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia

Info

Publication number
PL1894564T3
PL1894564T3 PL07023058T PL07023058T PL1894564T3 PL 1894564 T3 PL1894564 T3 PL 1894564T3 PL 07023058 T PL07023058 T PL 07023058T PL 07023058 T PL07023058 T PL 07023058T PL 1894564 T3 PL1894564 T3 PL 1894564T3
Authority
PL
Poland
Prior art keywords
constipation
prophylaxis
treatment
ibat inhibitor
ibat
Prior art date
Application number
PL07023058T
Other languages
English (en)
Inventor
Hasse Roland Abrahamsson
Per-Göran Gillberg
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9956272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1894564(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albireo Ab filed Critical Albireo Ab
Publication of PL1894564T3 publication Critical patent/PL1894564T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL07023058T 2003-04-05 2004-04-01 Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia PL1894564T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0307918.3A GB0307918D0 (en) 2003-04-05 2003-04-05 Therapeutic use
EP07023058A EP1894564B1 (en) 2003-04-05 2004-04-01 Use of an IBAT inhibitor for the treatment or prophylaxis of constipation
EP04725081A EP1610770B1 (en) 2003-04-05 2004-04-01 Use of an ibat inhibitor for the treatment or prophylaxis of constipation

Publications (1)

Publication Number Publication Date
PL1894564T3 true PL1894564T3 (pl) 2011-11-30

Family

ID=9956272

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07023058T PL1894564T3 (pl) 2003-04-05 2004-04-01 Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia
PL04725081T PL1610770T3 (pl) 2003-04-05 2004-04-01 Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04725081T PL1610770T3 (pl) 2003-04-05 2004-04-01 Zastosowanie inhibitora IBAT do leczenia lub profilaktyki zaparcia

Country Status (32)

Country Link
US (1) US7514421B2 (pl)
EP (2) EP1610770B1 (pl)
JP (2) JP4870552B2 (pl)
KR (1) KR101321577B1 (pl)
CN (1) CN100366241C (pl)
AR (1) AR043985A1 (pl)
AT (2) ATE387194T1 (pl)
AU (1) AU2004228731B2 (pl)
BR (1) BRPI0408858A (pl)
CA (1) CA2520109C (pl)
CO (1) CO5640076A2 (pl)
CY (2) CY1107424T1 (pl)
DE (1) DE602004012079T2 (pl)
DK (2) DK1610770T3 (pl)
ES (2) ES2368350T3 (pl)
GB (1) GB0307918D0 (pl)
IL (1) IL170913A (pl)
IS (1) IS8113A (pl)
MX (1) MXPA05010706A (pl)
MY (1) MY137757A (pl)
NO (1) NO335140B1 (pl)
NZ (1) NZ542835A (pl)
PL (2) PL1894564T3 (pl)
PT (2) PT1610770E (pl)
RU (2) RU2342928C2 (pl)
SA (1) SA04250066B1 (pl)
SI (2) SI1894564T1 (pl)
TW (1) TWI338577B (pl)
UA (1) UA84141C2 (pl)
UY (1) UY28258A1 (pl)
WO (1) WO2004089350A1 (pl)
ZA (1) ZA200507996B (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
KR101558005B1 (ko) * 2007-03-08 2015-10-06 알비레오 에이비 2-치환-3-페닐프로피온산 유도체 및 염증성 장 질환 치료에서의 그의 용도
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SI3023102T1 (sl) * 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
BR112014010228B1 (pt) 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
RU2015139731A (ru) 2013-03-15 2017-04-20 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
US20140271734A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
CA2952405A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for stabilizing the same
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN109310774A (zh) 2015-08-17 2019-02-05 费林股份公司 含有匹可硫酸盐和柠檬酸镁的液体制剂
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US20180015078A1 (en) 2016-07-08 2018-01-18 Ferring B.V. Stabilized liquid formulations containing picosulfate
FI3643718T3 (fi) 2017-06-20 2023-11-01 Takeda Pharmaceuticals Co Heterosyklinen yhdiste ja sen käyttö kolinergisen muskariini-m1-reseptorin positiivisena allosteerisena modulaattorina
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
EP3762370A1 (en) 2018-03-09 2021-01-13 Elobix Ab Process for the preparation of elobixibat
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3011850T3 (en) 2018-06-20 2025-04-08 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CA3127568A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
BR112021015815A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase
EP4029860A4 (en) 2019-09-09 2023-08-23 Elobix Ab PROCESS FOR PREPARING A 1,5-BENZOTHIAZEPINE COMPOUND
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP7695242B2 (ja) 2019-12-04 2025-06-18 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2022166680A1 (zh) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 奥德昔巴特的晶型及其制备方法和用途
AU2023255249A1 (en) 2022-04-22 2024-10-17 Albireo Ab Subcutaneous administration of an asbt inhibitor

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771072A (en) 1985-01-10 1988-09-13 Tanabe Seiyaku Co., Ltd. Alkoxynaphthalene derivatives
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
FI106800B (fi) 1990-12-06 2001-04-12 Hoechst Ag Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi
KR100252428B1 (ko) 1991-10-17 2000-04-15 시오노 요시히코 리그난유사체,이의제조방법및이를함유한항지혈증제
NZ245503A (en) 1991-12-20 1995-11-27 Hoechst Ag Polymers containing bile acids; pharmaceuticals and preparatory methods
JPH05186357A (ja) * 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
DK0573848T3 (da) 1992-06-12 1998-08-10 Hoechst Ag Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
US5488134A (en) 1993-04-16 1996-01-30 Shionogi & Co., Ltd. Preparation of compounds of lignan series
TW289021B (pl) 1993-05-08 1996-10-21 Hoechst Ag
TW289020B (pl) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
BR9508916A (pt) 1994-09-13 1997-12-30 Monsanto Co "Novas benzotiepinas tendo atividade como inibidores de transporte do ácido biliar ileal e absorção de taurocolato"
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
CA2248586A1 (en) 1996-03-11 1997-09-18 G.D. Searle & Co. Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP0929575A4 (en) 1996-08-23 2004-09-08 Human Genome Sciences Inc NEW HUMAN GROWTH FACTORS.
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
CN1255864A (zh) 1997-03-11 2000-06-07 G·D·瑟尔公司 使用回肠胆汁酸传输抑制苯并硫杂环庚三烯和HMGCo-A还原酶抑制剂的组合疗法
DE69815180T2 (de) 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
DK0869121T3 (da) 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
AUPO763197A0 (en) * 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
US6369220B1 (en) 1997-12-19 2002-04-09 Jinglin (James T.) Li Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU1684400A (en) 1998-12-11 2000-07-03 Sankyo Company Limited Substituted benzylamines
EP1354604A1 (en) 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
DK1140190T3 (da) 1998-12-23 2002-12-23 Searle Llc Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
DK1140191T3 (da) 1998-12-23 2003-02-24 Searle Llc Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer
CN1195748C (zh) 1999-02-12 2005-04-06 G.D.瑟尔有限公司 具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2-苯并硫氮杂
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
TR200002099A3 (tr) 1999-07-22 2001-06-21 Sankyo Company Limited Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari
AU1302301A (en) 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US6506921B1 (en) * 2001-06-29 2003-01-14 Virginia Tech Intellectual Properties, Inc. Amine compounds and curable compositions derived therefrom
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
AR036873A1 (es) * 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
WO2003022286A1 (en) 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
RU2008129204A (ru) 2010-01-27
SI1894564T1 (sl) 2011-08-31
CA2520109A1 (en) 2004-10-21
UY28258A1 (es) 2004-11-30
DE602004012079D1 (de) 2008-04-10
NO335140B1 (no) 2014-09-29
TWI338577B (en) 2011-03-11
ZA200507996B (en) 2007-04-25
ATE387194T1 (de) 2008-03-15
PT1894564E (pt) 2011-07-26
JP4870552B2 (ja) 2012-02-08
HK1085666A1 (en) 2006-09-01
NO20054369L (no) 2005-11-15
DE602004012079T2 (de) 2009-02-26
JP5421326B2 (ja) 2014-02-19
DK1610770T3 (da) 2008-05-13
US20060199797A1 (en) 2006-09-07
RU2005128792A (ru) 2006-05-10
WO2004089350A1 (en) 2004-10-21
SI1610770T1 (sl) 2008-06-30
ATE513550T1 (de) 2011-07-15
AR043985A1 (es) 2005-08-17
US7514421B2 (en) 2009-04-07
SA04250066B1 (ar) 2008-09-22
CY1107424T1 (el) 2012-12-19
TW200505434A (en) 2005-02-16
NO20054369D0 (no) 2005-09-21
DK1894564T3 (da) 2011-08-29
CO5640076A2 (es) 2006-05-31
CA2520109C (en) 2012-03-20
MXPA05010706A (es) 2005-12-12
EP1894564A3 (en) 2009-09-09
JP2006522082A (ja) 2006-09-28
ES2299832T3 (es) 2008-06-01
EP1894564A2 (en) 2008-03-05
NZ542835A (en) 2009-01-31
EP1610770B1 (en) 2008-02-27
EP1610770A1 (en) 2006-01-04
MY137757A (en) 2009-03-31
PT1610770E (pt) 2008-04-10
AU2004228731B2 (en) 2008-02-28
AU2004228731A1 (en) 2004-10-21
RU2482850C2 (ru) 2013-05-27
JP2011173925A (ja) 2011-09-08
EP1894564B1 (en) 2011-06-22
KR20050121241A (ko) 2005-12-26
IS8113A (is) 2005-11-01
GB0307918D0 (en) 2003-05-14
CN1771027A (zh) 2006-05-10
PL1610770T3 (pl) 2008-07-31
ES2368350T3 (es) 2011-11-16
UA84141C2 (ru) 2008-09-25
RU2342928C2 (ru) 2009-01-10
CN100366241C (zh) 2008-02-06
IL170913A (en) 2010-11-30
CY1111995T1 (el) 2015-11-04
BRPI0408858A (pt) 2006-04-11
KR101321577B1 (ko) 2013-10-25

Similar Documents

Publication Publication Date Title
ZA200507996B (en) Use of an IBAT inhibitor for the treatment or prophylaxis of constipation
ZA200501913B (en) New compounds for the inhibition of rotamases and use thereof
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
PL375532A1 (pl) Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
GB2418025B (en) Device for the prevention or treatment of ulcers
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003212634A8 (en) Compounds useful in the treatment of cancer
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
IL164899A0 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
PL375564A1 (pl) Podstawione 5-chroman-5-ylo-etyloaminy i ich zastosowanie do leczenia jaskry
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
AU2003270683A8 (en) Compounds for the treatment of premature ejaculation
AU2003205452A8 (en) Bmp inhibitors for the treatment of spondyloarthropathies
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
IL162492A0 (en) Use of alkylphosphocholines for the preventative treatment of protozoandiseases
AU2000272704A1 (en) Use of compounds for the treatment of obesity
IL170706A0 (en) Use of atii antagonist for the treatment or prevention of metabolic syndrome
AU2002343085A1 (en) Tnf-alpha inhibitors for the treatment of hepatic diseases
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or
GB0317128D0 (en) Use of antitumoral compounds